Parallel Advisors’s Immunovant IMVT Stock Holding History

Parallel Advisors’s Portfolio IMVT Stock Details IMVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.16K	Hold	108	–	–	﹤0.01%	3282
2026 Q1	$2.68K	Hold	108	–	–	﹤0.01%	3275
2025 Q4	$2.75K	Buy	108 +26	+32%	+$580	﹤0.01%	3045
2025 Q3	$1.32K	Sell	82 -1,224	-94%	-$19.8K	﹤0.01%	3150
2025 Q2	$20.9K	Buy	1,306 +1,299	+18,557%	+$19.6K	﹤0.01%	2171
2025 Q1	$120	Sell	7 -31	-82%	-$648	﹤0.01%	3429
2024 Q4	$941	Buy	+38	New	+$1.08K	﹤0.01%	3121
2023 Q2	–	Sell	-24	Closed	-$372	–	3446
2023 Q1	$372	Hold	24	–	–	﹤0.01%	3193
2022 Q4	$426	Hold	24	–	–	﹤0.01%	3062
2022 Q3	$0	Buy	+24	New	+$117	﹤0.01%	3314
2022 Q1	–	Sell	-382	Closed	-$3K	–	3105
2021 Q4	$3K	Buy	+382	New	+$3.15K	﹤0.01%	2579
2021 Q3	–	Sell	-14,262	Closed	-$151K	–	3160
2021 Q2	$151K	Hold	14,262	–	–	0.01%	803
2021 Q1	$229K	Buy	+14,262	New	+$376K	0.01%	593

Other funds holding IMVT

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Parallel Advisors's IMVT Position: Q2 2026 in Review

Parallel Advisors held its Immunovant (IMVT) position steady in Q2 2026 at 108 shares worth $4.16K. The position accounts for ﹤0.01% of the portfolio, ranked #3282.

Parallel Advisors first reported a position in IMVT in Q1 2021 and has held it in 13 quarters since. The position peaked at $229K in Q1 2021. 226 funds tracked by Wall St. Rank hold IMVT as of Q2 2026.

Parallel Advisors held 108 shares of Immunovant worth $4.16K as of Q2 2026.
Parallel Advisors left its Immunovant share count unchanged in Q2 2026.
Immunovant made up ﹤0.01% of Parallel Advisors's portfolio in Q2 2026, its #3282 holding.
Parallel Advisors first reported a position in Immunovant in Q1 2021 and has held it in 13 quarters since.
Parallel Advisors's Immunovant position peaked at $229K in Q1 2021.
226 funds tracked by Wall St. Rank held Immunovant as of Q2 2026.

Based on Parallel Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.